Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 327-336

  Yang, Zhiwen ^a,c   Chen, Meiwan ^b   Yang, Muhua ^a   Chen, Jian ^a   Fang, Weijun ^a   Xu, Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b University of Macau   (Macao)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Absorption mechanism; Amphotericin B; Antifungal activity; Glyceryl monoolein cubosomes; Oral delivery

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DRUG CARRIER; GLYCEROL OLEATE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CELL STRAIN CACO 2; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION MECHANISM; AMPHOTERICIN B; ANTIFUNGAL ACTIVITY; GLYCERYL MONOOLEIN CUBOSOMES; ORAL DELIVERY;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CACO-2 CELLS; CANDIDIASIS; FEASIBILITY STUDIES; HUMANS; MALE; NANOCAPSULES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84891806144     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S54967     Document Type: Article

References (35)

1. Benincasa M, Pacor S, Wu W, Prato M, Bianco A, Gennaro R. Antifungal activity of amphotericin B conjugated to carbon nanotubes. ACS Nano. 2011;5(1):199-208.
2. Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol Pharm. 2012;9(9):2542-2553.
3. Verma RK, Pandya S, Misra A. Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol. 2011;7(1):118-120.
4. Golenser J, Domb A. New formulations and derivatives of amphotericin B for treatment of leishmaniasis. Mini Rev Med Chem. 2006;6(2):153-162.
5. Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632-639.
6. Yang Z, Tan Y, Chen M, et al. Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability. AAPS PharmSciTech. 2012;13(4):1483-1491.
7. Yang Z, Peng X, Tan Y, et al. Optimization of the preparation process for an oral phytantriol-based amphotericin B cubosomes. J Nanomater. 2011 2011: Article ID 308016.
8. Wasan EK, Bartlett K, Gershkovich P, et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm. 2009;372(1-2):76-84.
9. Ibrahim F, Gershkovich P, Sivak O, Wasan EK, Bartlett K, Wasan KM. Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Int J Pharm. 2012;436(1-2):318-323.
10. Perlin DS. Amphotericin B cochleates: a vehicle for oral delivery. Curr Opin Investig Drugs. 2004;5(2):198-201.
11. Thornton SJ, Wasan KM. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv. 2009;6(3):271-284.
12. Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release. 2011;153(2):180-186.
13. Zhen G, Hinton TM, Muir BW, et al. Glycerol monooleate-based nano-carriers for siRNA delivery in vitro. Mol Pharm. 2012;9(9):2450-2457.
14. Hosmer JM, Steiner AA, Lopes LB. Lamellar liquid crystalline phases for cutaneous delivery of paclitaxel: Impact of the monoglyceride. Pharm Res. 2012;30(3):694-706.
15. Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140(2): 174-181.
16. Mo R, Jin X, Li N, et al. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles. Biomaterials. 2011;32(20):4609-4620.
17. Robbie G, Chiou WL. Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res. 1998;15(10):1630-1636.
18. Li N, Li XR, Zhou YX, et al. The use of polyion complex micelles to enhance the oral delivery of salmon calcitonin and transport mechanism across the intestinal epithelial barrier. Biomaterials. 2012;33(34): 8881-8892.
19. Vercauteren D, Rejman J, Martens TF, Demeester J, De Smedt SC, Braeckmans K. On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods. J Control Release. 2012;161(2):566-581.
20. Incecayir T, Tsume Y, Amidon GL. Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm. 2013;10(3): 958-966.
21. Frolund S, Langthaler L, Kall MA, Holm R, Nielsen CU. Intestinal drug transport via the proton-coupled amino acid transporter PAT1 (SLC36A1) is inhibited by Gly-X(aa) dipeptides. Mol Pharm. 2012;9(9):2761-2769.
22. Jahn MR, Nawroth T, Futterer S, Wolfrum U, Kolb U, Langguth P. Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells. Mol Pharm. 2012;9(6):1628-1637.
23. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm. June 13, 2012. [Epub ahead of print.]
24. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv. 2008;5(1):45-68.
25. Lin YH, Mi FL, Chen CT, et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules. 2007;8(1):146-152.
26. Vertzoni M, Markopoulos C, Symillides M, Goumas C, Imanidis G, Reppas C. Luminal lipid phases after administration of a triglyceride solution of danazol in the fed state and their contribution to the flux of danazol across Caco-2 cell monolayers. Mol Pharm. 2012;9(5):1189-1198.
27. Meng S, Wu B, Singh R, et al. SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol Pharm. 2012;9(4):862-873.
28. Risovic V, Sachs-Barrable K, Boyd M, Wasan KM. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm. 2004;30(7):767-774.
29. Rosenblatt KM, Douroumis D, Bunjes H. Drug release from differently structured monoolein/poloxamer nanodispersions studied with differential pulse polarography and ultrafiltration at low pressure. J Pharm Sci. 2007;96(6):1564-1575.
30. Fatouros DG, Bergenstahl B, Mullertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion. Eur J Pharm Sci. 2007;31(2):85-94.
31. Kossena GA, Charman WN, Wilson CG, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res. 2007;24(11):2084-2096.
32. Sachs-Barrable K, Lee SD, Wasan EK, Thornton SJ, Wasan KM. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev. 2008;60(6):692-701.
33. Risovic V, Boyd M, Choo E, Wasan KM. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother. 2003;47(10): 3339-3342.
34. Sivak O, Gershkovich P, Lin M, et al. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis. 2011;10:135.
35. Gershkovich P, Wasan EK, Lin M, et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009;64(1): 101-108.